Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

Muller, G W; Corral, L G; Shire, M G; Wang, H; Moreira, A; Kaplan, G; Stirling, D I

Muller, G W; Corral, L G; Shire, M G; Wang, H; Moreira, A; Kaplan, G; Stirling, D I.

Affiliation

Muller GW; Celgene Corporation, Warren, New Jersey 07059, USA.

J Med Chem ; 39(17): 3238-40, 1996 Aug 16.

Article in En | MEDLINE | ID: mdl-8765505

Subject(s)

Lymphocytes/immunology; Thalidomide/analogs & derivatives; Thalidomide/chemical synthesis; Tumor Necrosis Factor-alpha/biosynthesis; Humans; Kinetics; Lipopolysaccharides/pharmacology; Lymphocytes/drug effects; Molecular Structure; Phthalimides/chemical synthesis; Phthalimides/pharmacology; Pyrimidinones/chemical synthesis; Pyrimidinones/pharmacology; Structure-Activity Relationship; Thalidomide/pharmacology; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Lymphocytes / Tumor Necrosis Factor-alpha Limits: Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 1996 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links